CCEL
Cryo-Cell International, Inc.·Healthcare
3.35
1.471%(−0.05)
Close PriceLast Updated: — ET
52W L: $2.7252W H: $6.35
CCEL NEWS
businesswire.com
May 8
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company's previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co.
businesswire.com
Apr 28
Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company's latest FACT re-accreditation extends for three more years, with the latest renewal effective through Ap.
defenseworld.net
Apr 21
Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – What’s Next?
Cryo-Cell International Inc. (NYSEAMERICAN:CCEL - Get Free Report) shares passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $3.72 and traded as low as $3.41. Cryo-Cell International shares last traded at $3.56, with a volume of 10,098 shares. Cryo-Cell International Stock
businesswire.com
Apr 14
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million i.
defenseworld.net
Apr 3
Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – Should You Sell?
Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $3.82 and traded as low as $3.48. Cryo-Cell International shares last traded at $3.64, with a volume of 7,996 shares changing hands. Cryo-Cell International Price Performance
businesswire.com
Mar 12
Cryo-Cell Receives NYSE American Continued Listing Notice
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in com.
